source
- Merck pulls Recarbrio antibiotic from U.S. market, raising concerns over superbug resistanceMerck announced it has stopped supplying Recarbrio in the United States earlier this month. Recarbrio, a three‑drug combination injection approved seven years ago, is used for severe infections su…
- Kodiak Sciences reports Phase 3 success for Zenkuda, matching Eylea in wet AMDKodiak Sciences announced that its experimental therapy Zenkuda achieved comparable efficacy to the market‑leading anti‑VEGF drug Eylea in a late‑stage trial for wet age‑related macular degeneratio…